The Zacks Analyst Blog Highlights AppLovin, Duolingo, Paramount, Twilio and Catalent
Thermo Fisher Plant Making Astra/ Sanofi RSV Drug Reportedly Breached FDA Rules
Express News | Exclusive-Sanofi Says FDA Findings Were Addressed, All Beyfortus Doses Were Approved by FDA Before They Were Shipped
Express News | Exclusive-FDA's Most Recent Inspection of Thermo Fisher Plant Found Shortfalls in Manufacturing of AstraZeneca's and Sanofi's Beyfortus Rsv Treatment
Express News | Exclusive-FDA Says the Thermo Fisher Plant Addressed Concerns About Safety Issues Raised in the Audit
Express News | Exclusive-Thermo Fisher's Greenville, North Carolina Plant Was Found in Breach of US FDA Regulations, Documents Show
Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent's Analytical Services Laboratory in Research Triangle Park
Catalent Stock: Is CTLT Outperforming the Healthcare Sector?
Catalent Cut to Neutral at Baird as Analyst Unable to Find Valuation in a Deal Break
Catalent Analyst Ratings
Baird Downgrades Catalent to Neutral From Outperform, Price Target Is $63.50
Baird Downgrades Catalent(CTLT.US) to Hold Rating, Maintains Target Price $63.5
Baird analyst Eric Coldwell downgrades $Catalent(CTLT.US)$ to a hold rating, and maintains the target price at $63.5.According to TipRanks data, the analyst has a success rate of 53.9% and a total
Hold Rating on Catalent Amid Deal Uncertainties and Conservative Financial Outlook
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut
Do Options Traders Know Something About Catalent (CTLT) Stock We Don't?
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Decoding Catalent Inc (CTLT): A Strategic SWOT Insight
Catalent | 10-K: FY2024 Annual Report